| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.599 | 0.021 | 0.631 | MAP kinase 1 inhibitor | 0.631 0.013 DBMET03412 0.611 0.018 DBMET03413 | DBMET03412 | |
| 0.563 | 0.009 | 0.563 | Growth factor antagonist | 0.529 0.01 DBMET03412 0.556 0.009 DBMET03413 | ||
| 0.434 | 0.005 | 0.434 | Epidermal growth factor antagonist | 0.369 0.005 DBMET03412 0.407 0.005 DBMET03413 | ||
| 0.404 | 0.005 | 0.404 | Epidermal growth factor receptor kinase inhibitor | 0.359 0.006 DBMET03412 0.396 0.005 DBMET03413 | ||
| 0.436 | 0.043 | 0.452 | Angiogenesis inhibitor | 0.449 0.04 DBMET03412 0.452 0.039 DBMET03413 | DBMET03413 | |
| 0.369 | 0.004 | 0.369 | ErbB-4 antagonist | 0.325 0.005 DBMET03412 0.352 0.005 DBMET03413 | ||
| 0.39 | 0.047 | 0.39 | Immunomodulator | 0.355 0.058 DBMET03412 0.37 0.053 DBMET03413 | ||
| 0.334 | 0.004 | 0.334 | ErbB-3 antagonist | 0.304 0.004 DBMET03412 0.302 0.004 DBMET03413 | ||
| 0.35 | 0.036 | 0.35 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.315 0.054 DBMET03412 0.305 0.06 DBMET03413 | ||
| 0.305 | 0.042 | 0.305 | Antimitotic | 0.279 0.05 DBMET03412 0.285 0.048 DBMET03413 | ||
| 0.264 | 0.018 | 0.308 | Cyclin-dependent kinase 7 inhibitor | 0.245 0.022 DBMET03412 0.308 0.011 DBMET03413 | DBMET03413 | |
| 0.269 | 0.049 | 0.311 | Tyrosine kinase inhibitor | 0.248 0.054 DBMET03412 0.311 0.041 DBMET03413 | DBMET03413 | |
| 0.228 | 0.019 | 0.251 | Death-associated protein kinase 2 inhibitor | 0.225 0.021 DBMET03412 0.251 0.013 DBMET03413 | DBMET03413 | |
| 0.187 | 0.013 | 0.192 | ALK inhibitor | 0.179 0.014 DBMET03412 0.192 0.013 DBMET03413 | DBMET03413 | |
| 0.166 | 0.006 | 0.166 | Bruton tyrosine kinase inhibitor | 0.148 0.008 DBMET03412 0.151 0.008 DBMET03413 | ||
| 0.202 | 0.044 | 0.228 | Polo-like kinase-3 inhibitor | 0.199 0.046 DBMET03412 0.228 0.032 DBMET03413 | DBMET03413 | |
| 0.221 | 0.064 | 0.314 | Death-associated protein kinase 3 inhibitor | 0.219 0.065 DBMET03412 0.314 0.034 DBMET03413 | DBMET03413 | |
| 0.218 | 0.072 | 0.218 | ErbB-1 antagonist | 0.197 0.093 DBMET03412 0.218 0.072 DBMET03413 | ||
| 0.309 | 0.166 | 0.32 | Apoptosis agonist | 0.32 0.159 DBMET03412 0.297 0.174 DBMET03413 | DBMET03412 | |
| 0.165 | 0.023 | 0.165 | Insulin receptor antagonist | 0.108 0.052 DBMET03412 0.165 0.023 DBMET03413 | ||
| 0.144 | 0.005 | 0.166 | Fibroblast growth factor 4 antagonist | 0.166 0.005 DBMET03412 0.131 0.005 DBMET03413 | DBMET03412 | |
| 0.202 | 0.074 | 0.215 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.215 0.068 DBMET03412 0.213 0.069 DBMET03413 | DBMET03412 | |
| 0.127 | 0.013 | 0.137 | MAP3K7 inhibitor | 0.125 0.013 DBMET03412 0.137 0.011 DBMET03413 | DBMET03413 | |
| 0.167 | 0.055 | 0.167 | Lck kinase inhibitor | 0.158 0.06 DBMET03412 0.165 0.057 DBMET03413 | ||
| 0.141 | 0.034 | 0.16 | Fibroblast growth factor 1 antagonist | 0.16 0.028 DBMET03412 0.144 0.033 DBMET03413 | DBMET03412 | |
| 0.123 | 0.028 | 0.123 | Polo-like kinase-1 inhibitor | 0.112 0.035 DBMET03412 0.112 0.035 DBMET03413 | ||
| 0.166 | 0.073 | 0.166 | Src kinase inhibitor | 0.153 0.081 DBMET03412 0.162 0.075 DBMET03413 | ||
| 0.163 | 0.07 | 0.163 | Cyclin-dependent kinase 3 inhibitor | 0.163 0.071 DBMET03412 0.137 0.131 DBMET03413 | ||
| 0.152 | 0.064 | 0.173 | Protein-tyrosine kinase Lyn inhibitor | 0.124 0.081 DBMET03412 0.173 0.056 DBMET03413 | DBMET03413 | |
| 0.093 | 0.013 | 0.093 | Cyclin-dependent kinase 6 inhibitor | 0.073 0.028 DBMET03412 0.076 0.025 DBMET03413 | ||
| 0.105 | 0.026 | 0.105 | Focal adhesion kinase 1 inhibitor | 0.105 0.026 DBMET03412 0.102 0.028 DBMET03413 | ||
| 0.139 | 0.066 | 0.174 | Aurora-C kinase inhibitor | 0.152 0.048 DBMET03412 0.174 0.03 DBMET03413 | DBMET03413 | |
| 0.136 | 0.063 | 0.158 | Cyclin-dependent kinase inhibitor | 0.123 0.072 DBMET03412 0.158 0.052 DBMET03413 | DBMET03413 | |
| 0.092 | 0.019 | 0.098 | Protein kinase C eta inhibitor | 0.098 0.018 DBMET03412 0.05 0.043 DBMET03413 | DBMET03412 | |
| 0.111 | 0.04 | 0.111 | Insulin growth factor antagonist | 0.099 0.047 DBMET03412 0.11 0.04 DBMET03413 | ||
| 0.091 | 0.021 | 0.128 | Tyrosine-protein kinase EMT inhibitor | 0.085 0.023 DBMET03412 0.128 0.012 DBMET03413 | DBMET03413 | |
| 0.127 | 0.059 | 0.129 | Platelet activating factor antagonist | 0.106 0.073 DBMET03412 0.129 0.057 DBMET03413 | DBMET03413 | |
| 0.097 | 0.028 | 0.103 | Polo-like kinase-2 inhibitor | 0.102 0.024 DBMET03412 0.103 0.023 DBMET03413 | DBMET03413 | |
| 0.179 | 0.111 | 0.239 | Dyrk kinase inhibitor | 0.16 0.126 DBMET03412 0.239 0.077 DBMET03413 | DBMET03413 | |
| 0.137 | 0.069 | 0.156 | Interleukin 1 antagonist | 0.112 0.101 DBMET03412 0.156 0.053 DBMET03413 | DBMET03413 | |
| 0.172 | 0.104 | 0.183 | Proto-oncogene tyrosine-protein kinase Fyn inhibitor | 0.172 0.104 DBMET03412 0.183 0.09 DBMET03413 | DBMET03413 | |
| 0.146 | 0.08 | 0.182 | Ca2+/calmodulin-dependent protein kinase kinase B inhibitor | 0.139 0.094 DBMET03412 0.182 0.03 DBMET03413 | DBMET03413 | |
| 0.073 | 0.01 | 0.087 | CDK7/cyclin H inhibitor | 0.067 0.012 DBMET03412 0.087 0.007 DBMET03413 | DBMET03413 | |
| 0.102 | 0.04 | 0.102 | Insulin like growth factor 1 antagonist | 0.092 0.048 DBMET03412 0.101 0.041 DBMET03413 | ||
| 0.087 | 0.025 | 0.089 | ZAP-70 protein tyrosine kinase inhibitor | 0.089 0.024 DBMET03412 0.087 0.025 DBMET03413 | DBMET03412 | |
| 0.114 | 0.054 | 0.114 | Platelet activating factor beta antagonist | 0.104 0.06 DBMET03412 0.114 0.054 DBMET03413 | ||
| 0.081 | 0.021 | 0.103 | Transcription factor AP-1 inhibitor | 0.079 0.022 DBMET03412 0.103 0.012 DBMET03413 | DBMET03413 | |
| 0.135 | 0.075 | 0.135 | Cytokine production inhibitor | |||
| 0.117 | 0.059 | 0.12 | CDK3/cyclin E inhibitor | 0.12 0.055 DBMET03412 0.11 0.07 DBMET03413 | DBMET03412 | |
| 0.131 | 0.076 | 0.154 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.154 0.063 DBMET03412 0.118 0.086 DBMET03413 | DBMET03412 | |
| 0.092 | 0.037 | 0.139 | Janus tyrosine kinase 3 inhibitor | 0.085 0.041 DBMET03412 0.139 0.021 DBMET03413 | DBMET03413 | |
| 0.085 | 0.03 | 0.085 | MAP kinase 7 inhibitor | 0.083 0.034 DBMET03412 0.076 0.061 DBMET03413 | ||
| 0.093 | 0.039 | 0.103 | ErbB-2 antagonist | 0.081 0.047 DBMET03412 0.103 0.034 DBMET03413 | DBMET03413 | |
| 0.129 | 0.078 | 0.134 | Toll-Like receptor 9 antagonist | 0.134 0.074 DBMET03412 | DBMET03412 | |
| 0.083 | 0.033 | 0.083 | Cyclin-dependent kinase 4 inhibitor | 0.073 0.039 DBMET03412 0.075 0.038 DBMET03413 | ||
| 0.074 | 0.029 | 0.079 | CDK9/cyclin T1 inhibitor | 0.073 0.029 DBMET03412 0.079 0.027 DBMET03413 | DBMET03413 | |
| 0.079 | 0.035 | 0.079 | Protein kinase C alpha inhibitor | 0.075 0.038 DBMET03412 | ||
| 0.162 | 0.12 | 0.218 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.143 0.136 DBMET03412 0.218 0.082 DBMET03413 | DBMET03413 | |
| 0.278 | 0.237 | 0.28 | Antiinflammatory | 0.28 0.234 DBMET03412 | DBMET03412 | |
| 0.13 | 0.095 | 0.145 | MAP3K9 inhibitor | 0.125 0.103 DBMET03412 0.145 0.068 DBMET03413 | DBMET03413 | |
| 0.087 | 0.066 | 0.087 | Protein kinase C delta inhibitor | 0.087 0.066 DBMET03412 0.081 0.075 DBMET03413 | ||
| 0.101 | 0.081 | 0.109 | Vascular endothelial growth factor antagonist | 0.102 0.08 DBMET03412 0.109 0.075 DBMET03413 | DBMET03413 | |
| 0.123 | 0.104 | 0.156 | Dual specificity tyrosine-phosphorylation regulated kinase 1B inhibitor | 0.156 0.069 DBMET03413 | DBMET03413 | |
| 0.084 | 0.065 | 0.089 | CDK/cyclin complex inhibitor | 0.077 0.072 DBMET03412 0.089 0.06 DBMET03413 | DBMET03413 | |
| 0.087 | 0.071 | 0.087 | CDK2/cyclin A inhibitor | 0.083 0.076 DBMET03412 0.087 0.071 DBMET03413 | ||
| 0.035 | 0.019 | 0.035 | Protein kinase C beta I inhibitor | 0.034 0.021 DBMET03412 | ||
| 0.093 | 0.077 | 0.099 | Vascular endothelial growth factor 2 antagonist | 0.094 0.076 DBMET03412 0.099 0.072 DBMET03413 | DBMET03413 | |
| 0.062 | 0.049 | 0.081 | Fibroblast growth factor 2 antagonist | 0.081 0.033 DBMET03412 0.077 0.036 DBMET03413 | DBMET03412 | |
| 0.153 | 0.141 | 0.172 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.172 0.116 DBMET03413 | DBMET03413 | |
| 0.089 | 0.077 | 0.092 | Cyclin-dependent kinase 9 inhibitor | 0.092 0.072 DBMET03413 | DBMET03413 | |
| 0.089 | 0.084 | 0.097 | Cyclin-dependent kinase 2 inhibitor | 0.088 0.086 DBMET03412 0.097 0.074 DBMET03413 | DBMET03413 | |
| 0.031 | 0.027 | 0.031 | Protein kinase C beta II inhibitor | |||
| 0.059 | 0.061 | 0.061 | CDK1/cyclin B1 inhibitor | 0.061 0.06 DBMET03412 | DBMET03412 | |
| 0.141 | 0.145 | 0.164 | Focal adhesion kinase 2 inhibitor | 0.164 0.109 DBMET03413 | DBMET03413 | |
| 0.074 | 0.089 | 0.086 | Platelet activating factor alpha antagonist | 0.086 0.073 DBMET03413 | DBMET03413 | |
| 0.067 | 0.091 | 0.077 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.077 0.068 DBMET03413 | DBMET03413 | |
| 0.116 | 0.148 | 0.138 | MAP kinase 3 inhibitor | 0.138 0.089 DBMET03413 | DBMET03413 | |
| 0.076 | 0.109 | 0.106 | Protein kinase (CK2) alpha inhibitor | 0.106 0.071 DBMET03413 | DBMET03413 | |
| 0.091 | 0.132 | 0.172 | Dual specificity tyrosine-phosphorylation-regulated kinase 4 inhibitor | 0.172 0.064 DBMET03413 | DBMET03413 | |
| 0.051 | 0.097 | 0.076 | Fibroblast growth factor 3 antagonist | 0.076 0.056 DBMET03412 | DBMET03412 | |
| 0.089 | 0.144 | 0.109 | Protein kinase C nu inhibitor | 0.109 0.107 DBMET03413 | DBMET03413 | |
| 0.101 | 0.158 | 0.126 | Interleukin-1 receptor-associated protein kinase 1 inhibitor | 0.126 0.12 DBMET03413 | DBMET03413 | |
| 0.047 | 0.11 | 0.069 | MAP kinase 10 inhibitor | 0.069 0.066 DBMET03413 | DBMET03413 | |
| 0.109 | 0.173 | 0.177 | Interleukin antagonist | 0.177 0.098 DBMET03413 | DBMET03413 | |
| 0.083 | 0.154 | 0.125 | CDC-like kinase 1 inhibitor | 0.125 0.09 DBMET03413 | DBMET03413 | |
| 0.074 | 0.212 | 0.146 | Dual specificity tyrosine-phosphorylation regulated kinase 3 inhibitor | 0.146 0.124 DBMET03413 | DBMET03413 | |
| 0.125 | 0.487 | 0.317 | Calcium channel L-type activator | 0.317 0.143 DBMET03412 | DBMET03412 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |